Full video transcriptClick to expand
Auto-generated transcript of @kelleyrosspharmac's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Let's prepare a brand new Lyracletide pen for injection.
- 0:04Heads up, this video will show a lancet.
- 0:06Lyracletide, brand name Victoria, is a once daily, non-insulin, injectable medication commonly
- 0:11used in type 2 diabetes.
- 0:13When using your pen for the first time, take off the cap and visually inspect the medication,
- 0:17which should be clear in color and free of anything floating in it.
- 0:19I also like to check the expiration date of the pen to make sure it's not expired.
- 0:24Prep the pen by applying an alcohol wipe to the rubber stopper and then use a separate
- 0:29alcohol wipe on your skin where you will inject the medication.
- 0:32Next, prep your lancet by pulling the cover off, visually inspecting it, pushing it straight
- 0:37onto the pen and twisting it on to secure it.
- 0:40From here you can pull the outer cover off your lancet, but keep it nearby, you'll be
- 0:43using it later.
- 0:44For the first time you use this pen, you'll twist the dial to the flow check symbol, which
- 0:48looks like two dashes.
- 0:51Remove the inner needle cover and push down on the dial and you'll see small droplets.
- 0:55This is normal.
- 0:56Your pen is now ready for use.
- 0:58Use the dial to your dose and give your injection.
- 1:09After the injection, use the outer needle cover and place it over the lancet.
- 1:18Twist it off and put into your sharps container.
- 1:24Put the pen cap back on and you're all done.
Liraglutide pen prep: what the pharmacist gets right and wrong
Quick answer
Liraglutide is an FDA-approved GLP-1 receptor agonist available as Victoza for type 2 diabetes management and as Saxenda for chronic weight management, both administered via subcutaneous injection once daily. The video focuses on the mechanical preparation of the Victoza pen, which requires a flow check on first use, a step specific to multi-dose injection pen devices that confirms needle patency before the first therapeutic dose. Patients should be counseled separately on injection site rotation, storage requirements, and the distinction between pen needles and lancets to avoid dispensing errors.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 5 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Liraglutide pen prep: what the pharmacist gets right and wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Liraglutide pen prep: what the pharmacist gets right and wrong should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Liraglutide pen prep: what the pharmacist gets right and wrong" from kelleyrosspharmacy. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Liraglutide is an FDA-approved GLP-1 receptor agonist available as Victoza for type 2 diabetes management and as Saxenda for chronic weight management, both administered via subcutaneous injection once daily.
The reason this review is not generic is the source wording and the canonical claim label "glp1 prep a new liraglutide pen with me liraglutide brand name vi." In this clip, the useful excerpt is: "Let's prepare a brand new Lyracletide pen for injection." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Liraglutide is an FDA-approved GLP-1 receptor agonist available as Victoza for type 2 diabetes management and as Saxenda for chronic weight management, both administered via subcutaneous injection once daily.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Liraglutide is an FDA-approved GLP-1 receptor agonist available as Victoza for type 2 diabetes management and as Saxenda for chronic weight management, both administered via subcutaneous injection once daily. The video focuses on the mechanical preparation of the Victoza pen, which requires a flow check on first use, a step specific to multi-dose injection pen devices that confirms needle patency before the first therapeutic dose. Patients should be counseled separately on injection site rotation, storage requirements, and the distinction between pen needles and lancets to avoid dispensing errors.
- Liraglutide (Victoza) is FDA-approved for type 2 diabetes as a once-daily subcutaneous injection and is not insulin, per the 2010 FDA approval and current prescribing label.
- The pen needle attached to the Victoza pen is not a lancet. Lancets are fingertip-pricking devices for glucose monitoring. Calling a pen needle a lancet is a factual error that could cause patients to request the wrong product.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Liraglutide (Victoza) is FDA-approved for type 2 diabetes as a once-daily subcutaneous injection and is not insulin, per the 2010 FDA approval and current prescribing label.
- The pen needle attached to the Victoza pen is not a lancet. Lancets are fingertip-pricking devices for glucose monitoring. Calling a pen needle a lancet is a factual error that could cause patients to request the wrong product.
- A flow check on first use is required for the Victoza pen to confirm the needle is working. The two-dash symbol and appearance of a small droplet indicate the pen is ready, per Novo Nordisk patient instructions.
- Unopened Victoza pens require refrigeration between 36 and 46 degrees Fahrenheit. Once in use, they can be stored at room temperature below 77 degrees Fahrenheit for no more than 30 days.
- Victoza and Saxenda both contain liraglutide but are approved for different indications at different doses and are not interchangeable. Patients should never assume one product can substitute for the other.
- Visual inspection before each injection, checking for clarity and absence of particles, is a standard safety step supported by FDA prescribing information and applies to all injectable biologics, not just GLP-1 receptor agonists.
- Needle length for pen injections should be selected in consultation with a clinician or pharmacist, as subcutaneous injection depth varies by body composition and site.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @kelleyrosspharmac actually say?
A pharmacist at Kelley Ross walked through the steps for priming a new liraglutide pen for the first time. She described liraglutide as "a once daily, non-insulin, injectable medication commonly used in type 2 diabetes" and demonstrated a specific sequence: visual inspection, alcohol wipes on the rubber stopper and skin, needle attachment, a flow check using the "two dashes" symbol, and finally proper needle disposal into a sharps container.
She also used the word "lancet" throughout to describe the needle attachment for the pen. The video is clearly educational and procedural, aimed at patients who are new to this medication. No specific doses were mentioned, and no therapeutic claims beyond the general diabetes indication were made. That restraint is worth noting.
Does the science back this up?
Yes, in most respects. The procedural steps she described align with the FDA-approved prescribing information and Novo Nordisk's own patient instructions for Victoza. The flow check step, sometimes called a "priming" step, is standard for multi-dose injection pens and is designed to confirm the needle is patent and the device is working correctly.
The recommendation to inspect for clarity and absence of particulates before injection is supported by basic pharmacological safety practice. Injectable biologics and GLP-1 receptor agonists can degrade, and a cloudy or particulate-containing solution should not be used. The 2019 Victoza prescribing information from the FDA explicitly states the solution should be clear, colorless, and free of particles. Applying alcohol to both the rubber stopper and the injection site before use is consistent with standard aseptic technique guidelines, including those outlined by the CDC for home injectable medication use.
What did they get wrong (or right)?
The biggest factual error is a terminology one. She repeatedly called the needle a "lancet." That is incorrect. A lancet is a small, spring-loaded device used to prick a fingertip for blood glucose testing. The device used with the Victoza pen is a pen needle, not a lancet. These are different products with different designs and different purposes.
This is not a trivial distinction. Patients new to injectable therapy are already navigating unfamiliar equipment. Using the wrong term could genuinely confuse someone who goes to a pharmacy asking for lancets for their liraglutide pen. Credit where it is due: everything else in the procedural walkthrough was accurate and well-organized. She correctly described the two-dash flow check symbol, the proper direction for twisting the needle on, and the importance of recapping the needle using the outer cover before disposal, which reduces needlestick risk.
What should you actually know?
If you are starting liraglutide for the first time, the pen prep steps shown here are a reasonable guide, but your pharmacist or prescribing clinician should walk you through it in person or via a verified patient instruction sheet before your first injection. The Victoza pen uses NovoFine or compatible pen needles, which are sold separately and come in different lengths and gauges. Needle length matters for subcutaneous injection depth, and that choice should be made with your provider.
Storage also matters and was not covered in the video. Unopened Victoza pens must be refrigerated between 36 and 46 degrees Fahrenheit. Once in use, they can be stored at room temperature below 77 degrees Fahrenheit for up to 30 days. Injecting a pen that has been stored improperly, even one that looks visually clear, may result in reduced efficacy. Finally, liraglutide is also marketed as Saxenda at a higher dose for weight management. These are not interchangeable, and the dosing protocols differ significantly.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
kelleyrosspharmacy · TikTok creator
13.2K views on this video
Prep a new liraglutide pen with me! Liraglutide, brand name Victoza, is a once daily non-insulin injectable medication commonly used in type 2 diabetes. Got a pharmacy related question? Send us a message, comment below, or use our AskThePharmacist link in our bio to get your questions answered by a pharmacist! #kelleyross #pharmacist #liraglutide #victoza #communitypharmacy
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about liraglutide (victoza)?
Liraglutide (Victoza) is FDA-approved for type 2 diabetes as a once-daily subcutaneous injection and is not insulin, per the 2010 FDA approval and current prescribing label.
What does the video say about the pen needle attached to the victoza pen?
The pen needle attached to the Victoza pen is not a lancet. Lancets are fingertip-pricking devices for glucose monitoring. Calling a pen needle a lancet is a factual error that could cause patients to request the wrong product.
What does the video say about a flow check on first use?
A flow check on first use is required for the Victoza pen to confirm the needle is working. The two-dash symbol and appearance of a small droplet indicate the pen is ready, per Novo Nordisk patient instructions.
What does the video say about unopened victoza pens require refrigeration between 36?
Unopened Victoza pens require refrigeration between 36 and 46 degrees Fahrenheit. Once in use, they can be stored at room temperature below 77 degrees Fahrenheit for no more than 30 days.
What does the video say about victoza?
Victoza and Saxenda both contain liraglutide but are approved for different indications at different doses and are not interchangeable. Patients should never assume one product can substitute for the other.
What does the video say about visual inspection before each injection, checking for clarity?
Visual inspection before each injection, checking for clarity and absence of particles, is a standard safety step supported by FDA prescribing information and applies to all injectable biologics, not just GLP-1 receptor agonists.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by kelleyrosspharmacy, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.